Xenon Pharmaceuticals (XENE) Current Deferred Revenue (2013 - 2021)
Xenon Pharmaceuticals (XENE) posted quarterly Current Deferred Revenue of $2.2 million for Q3 2021, down 70.43% year-over-year from $7.4 million in Q3 2020, and down 27.21% quarter-over-quarter from $3.0 million in Q2 2021.
Xenon Pharmaceuticals (XENE) Current Deferred Revenue (2013 - 2021) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Current Deferred Revenue for 6 consecutive years, with $2.2 million the latest figure, recorded in Q3 2021.
- In Q3 2021, Current Deferred Revenue fell 70.43% year-over-year to $2.2 million; the TTM figure through Sep 2021 stood at $2.2 million (down 70.43% YoY), while the FY2020 annual figure was $3.6 million, down 87.76% from the prior year.
- Current Deferred Revenue declined to $2.2 million in Q3 2021 per XENE's latest filing, from $3.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $29.7 million in Q4 2019 and bottomed at $2.2 million in Q3 2021.
- Historically, Current Deferred Revenue has averaged $10.9 million across 3 years, with a median of $5.5 million in 2020.
- Annual changes were most pronounced in 2020 — Current Deferred Revenue plunged 87.76% — and 2021, when it slumped 70.43%.
- Xenon Pharmaceuticals' Current Deferred Revenue stood at $29.7 million in 2019, then slumped by 87.76% to $3.6 million in 2020, then sank by 39.54% to $2.2 million in 2021.
- Business Quant data shows XENE's Current Deferred Revenue at $2.2 million in Q3 2021, $3.0 million in Q2 2021, and $3.6 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 2.20 Mn |
| Jun 30, 2021 | 3.03 Mn |
| Mar 31, 2021 | 3.64 Mn |
| Dec 31, 2020 | 3.64 Mn |
| Sep 30, 2020 | 7.45 Mn |
| Jun 30, 2020 | 12.69 Mn |
| Mar 31, 2020 | 24.61 Mn |
| Dec 31, 2019 | 29.74 Mn |
| Dec 31, 2015 | 157,000.00 |
| Sep 30, 2015 | 2.51 Mn |
| Jun 30, 2015 | 5.64 Mn |
| Mar 31, 2015 | 8.72 Mn |
| Dec 31, 2014 | 11.62 Mn |
| Sep 30, 2014 | 13.52 Mn |
| Dec 31, 2013 | 15.92 Mn |